Literature DB >> 23543527

Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.

Manoj N Malviya1, Arne Ohlsson, Sachin S Shah.   

Abstract

BACKGROUND: A patent ductus arteriosus (PDA) with significant left to right shunt increases morbidity and mortality in preterm infants. Early closure of the ductus arteriosus may be achieved pharmacologically or by surgery. The preferred initial treatment of a symptomatic PDA, surgical ligation or treatment with indomethacin, is not clear.
OBJECTIVES: To compare the effect of surgical ligation of PDA versus medical treatment with cyclooxygenase inhibitors (indomethacin, ibuprofen or mefenamic acid), each used as the initial treatment, on neonatal mortality in preterm infants with a symptomatic PDA. SEARCH
METHODS: For this update we searched The Cochrane Library 2012, Issue 2, MEDLINE, EMBASE, CINAHL, Clinicaltrials.gov, Controlled-trials.com, Proceedings of the Annual Meetings of the Pediatric Academic Societies (2000 to 2011) (Abstracts2View(TM)) and Web of Science on 8 February 2012. SELECTION CRITERIA: Randomised or quasi-randomised trials in preterm or low birth weight neonates with symptomatic PDA and comparing surgical ligation with medical treatment with cyclooxygenase inhibitors, each used as the initial treatment for closure of PDA. DATA COLLECTION AND ANALYSIS: The authors independently assessed methodological quality and extracted data for the included trial. We used RevMan 5.1 for analyses of the data. MAIN
RESULTS: One study reporting on 154 neonates was found eligible. No significant difference between surgical closure and indomethacin treatment was found for in-hospital mortality, chronic lung disease, necrotising enterocolitis, sepsis, creatinine level or intraventricular haemorrhage. There was a significant increase in the surgical group in the incidence of pneumothorax (risk ratio (RR) 2.68; 95% confidence interval (CI) 1.45 to 4.93; risk difference (RD) 0.25; 95% CI 0.11 to 0.38; number needed to treat to harm (NNTH) 4 (95% CI 3 to 9)) and retinopathy of prematurity stage III and IV (RR 3.80; 95% CI 1.12 to 12.93; RD 0.11; 95% CI 0.02 to 0.20; NNTH 9 (95% CI 5 to 50)) compared to the indomethacin group. There was a statistically significant decrease in failure of ductal closure rate in the surgical group as compared to the indomethacin group (RR 0.04; 95% CI 0.01 to 0.27; RD -0.32; 95% CI -0.43 to -0.21, number needed to treat to benefit (NNTB) 3 (95% CI 2 to 4)). No new trials were identified for inclusion in the 2012 update. AUTHORS'
CONCLUSIONS: There are insufficient data to conclude whether surgical ligation or medical treatment with indomethacin is preferred as the initial treatment for symptomatic PDA in preterm infants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23543527      PMCID: PMC7027388          DOI: 10.1002/14651858.CD003951.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  64 in total

Review 1.  Prophylactic indomethacin: systematic review and meta-analysis.

Authors:  P W Fowlie
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-03       Impact factor: 5.747

2.  Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus.

Authors:  J Patel; I Roberts; D Azzopardi; P Hamilton; A D Edwards
Journal:  Pediatr Res       Date:  2000-01       Impact factor: 3.756

3.  An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity.

Authors: 
Journal:  Arch Ophthalmol       Date:  1984-08

4.  The contribution of PDA in the neonate with severe RDS.

Authors:  J Jacob; L Gluck; T DiSessa; D Edwards; M Kulovich; J Kurlinski; T A Merritt; W F Friedman
Journal:  J Pediatr       Date:  1980-01       Impact factor: 4.406

5.  Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging.

Authors:  F van Bel; G L Guit; J Schipper; M van de Bor; J Baan
Journal:  J Pediatr       Date:  1991-04       Impact factor: 4.406

6.  Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis.

Authors:  M A Heymann; A M Rudolph; N H Silverman
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

7.  Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin.

Authors:  J L Grosfeld; M Chaet; F Molinari; W Engle; S A Engum; K W West; F J Rescorla; L R Scherer
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

8.  Pharmacologic closure of patent ductus arteriosus in the premature infant.

Authors:  W F Friedman; M J Hirschklau; M P Printz; P T Pitlick; S E Kirkpatrick
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

9.  Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus.

Authors:  P Davis; S Turner-Gomes; K Cunningham; C Way; R Roberts; B Schmidt
Journal:  Arch Pediatr Adolesc Med       Date:  1995-10

10.  Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging.

Authors:  M J Bell; J L Ternberg; R D Feigin; J P Keating; R Marshall; L Barton; T Brotherton
Journal:  Ann Surg       Date:  1978-01       Impact factor: 12.969

View more
  19 in total

Review 1.  Potential and Limitations of Cochrane Reviews in Pediatric Cardiology: A Systematic Analysis.

Authors:  Martin Poryo; Sara Khosrawikatoli; Hashim Abdul-Khaliq; Sascha Meyer
Journal:  Pediatr Cardiol       Date:  2017-02-27       Impact factor: 1.655

2.  Nonsteroidal anti-inflammatory administration and patent ductus arteriosus ligation, a survey of practice preferences at US children's hospitals.

Authors:  Jonathan L Slaughter; Patricia B Reagan; Roopali V Bapat; Thomas B Newman; Mark A Klebanoff
Journal:  Eur J Pediatr       Date:  2016-02-15       Impact factor: 3.183

3.  Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus.

Authors:  Sarah Louise Harris; Kiran More; Bronwyn Dixon; Richard Troughton; Chris Pemberton; John Horwood; Nicola Ellis; Nicola Austin
Journal:  Eur J Pediatr       Date:  2018-01-19       Impact factor: 3.183

4.  Patent ductus arteriosus in premature infants: to treat or not to treat?

Authors:  M A Mohamed; M El-Dib; S Alqahtani; K Alyami; A N Ibrahim; H Aly
Journal:  J Perinatol       Date:  2017-02-16       Impact factor: 2.521

5.  Surgery-Associated Infections among Infants Born Extremely Preterm.

Authors:  Andi L Shane; Nellie I Hansen; Mohannad Moallem; Myra H Wyckoff; Pablo J Sánchez; Barbara J Stoll
Journal:  J Pediatr       Date:  2021-08-27       Impact factor: 4.406

6.  Trends in Patent Ductus Arteriosus Diagnosis and Management for Very Low Birth Weight Infants.

Authors:  Samantha Ngo; Jochen Profit; Jeffrey B Gould; Henry C Lee
Journal:  Pediatrics       Date:  2017-04       Impact factor: 7.124

7.  Indomethacin for symptomatic patent ductus arteriosus in preterm infants.

Authors:  Peter Evans; Deirdre O'Reilly; Jonathan N Flyer; Roger Soll; Souvik Mitra
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

8.  Relative effectiveness and safety of pharmacotherapeutic agents for patent ductus arteriosus (PDA) in preterm infants: a protocol for a multicentre comparative effectiveness study (CANRxPDA).

Authors:  Souvik Mitra; Amish Jain; Joseph Y Ting; Nadya Ben Fadel; Christine Drolet; Ayman Abou Mehrem; Amuchou Soraisham; Bonny Jasani; Deepak Louis; Anie Lapointe; Jon Dorling; Faiza Khurshid; Abbas Hyderi; Kumar Kumaran; Jaya Bodani; Dany Weisz; Ruben Alvaro; Mohammed Adie; Miroslav Stavel; Alyssa Morin; Soume Bhattacharya; Jaideep Kanungo; Rody Canning; Xiang Y Ye; Tara Hatfield; Courtney E Gardner; Prakesh Shah
Journal:  BMJ Open       Date:  2021-05-05       Impact factor: 2.692

9.  Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews.

Authors:  Emily Shepherd; Rehana A Salam; Philippa Middleton; Shanshan Han; Maria Makrides; Sarah McIntyre; Nadia Badawi; Caroline A Crowther
Journal:  Cochrane Database Syst Rev       Date:  2018-06-20

10.  Efficacy of a first course of Ibuprofen for patent ductus arteriosus closure in extremely preterm newborns according to their gestational age-specific Z-score for birth weight.

Authors:  Doriane Madeleneau; Marie-Stephanie Aubelle; Charlotte Pierron; Emmanuel Lopez; Juliana Patkai; Jean-Christophe Roze; Pierre-Henri Jarreau; Geraldine Gascoin
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.